A pharmaceutical composition merges lycopene with specific phytosterols to inhibit prostate cell growth.
Formula I macrolides inhibit fungal growth via parameter changes, resolving suboptimal treatment effectiveness.
Segmented microfluidization and filtration reduce large droplets to enhance emulsion stability for vaccine adjuvants.
Compounds inhibit Ras signaling to treat cancers resistant to EGFR inhibitors, reducing phospho-Akt, Mek, and Erk levels.